Clinical Impact of CYP2C19 Genotype on Clopidogrel-Based Antiplatelet Therapy After Percutaneous Coronary Intervention
JACC: Cardiovascular Interventions · 2023-04 · 16 (7) · 829-843
DOI: 10.1016/j.jcin.2023.01.363 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift JACC: Cardiovascular Interventions, 2023-04. Verfasst von Seung Hun Lee und 25 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Internal Medicine, Heart Center, Chonnam National University Hospital, Chonnam National University Medical Scho…. Hauptthemen laut MEDLINE: Acute Coronary Syndrome, Drug-Eluting Stents, Percutaneous Coronary Intervention. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 39 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Although there is a growing body of evidence that CYP2C19 genotyping can be beneficial when considering treatment with clopidogrel after percutaneous coronary intervention (PCI), whether a genotype-guided strategy can be generally adopted in routine practice remains unclear among East Asians. OBJECTIVES: This study sought to investigate long-term outcomes of patients undergoing clopidogrel-based antiplatelet therapy after drug-eluting stent (DES) implantation according to CYP2C19 genotypes. METHODS: From the nationwide multicenter PTRG-DES (Platelet function and genoType-Related long-term proGnosis in DES-treated patients) consortium, patients who underwent CYP2C19 genotyping were selected and classified according to CYP2C19 loss-of-function allele: rapid metabolizers (RMs) or normal metabolizers (NMs) vs intermediate metabolizers (IMs) or poor metabolizers (PMs). The primary outcome was a composite of cardiac death, myocardial infarction, and stent thrombosis at 5 years after the index procedure. RESULTS: Of 8,163 patients with CYP2C19 genotyping, 56.7% presented with acute coronary syndrome. There were 3,098 (37.9%) in the RM or NM group, 3,906 (47.9%) in the IM group, and 1,159 (14.2%) in the PM group. IMs or PMs were associated with an increased risk of 5-year primary outcome compared with RMs or NMs (HRadj: 1.42; 95% CI: 1.01-1.98; P = 0.041), and the effect was more pronounced in the first year (HRadj: 1.67; 95% CI: 1.10-2.55; P = 0.016). The prognostic implication of being an IM and PM was significant in acute coronary syndrome patients (HRadj: 1.88; 95% CI: 1.20-2.93; P = 0.005) but not in those with stable angina (HRadj: 0.92; 95% CI: 0.54-1.55; P = 0.751) (interaction P = 0.028). CONCLUSIONS: Among East Asians with clopidogrel-based antiplatelet therapy after DES implantation, CYP2C19 genotyping could stratify patients who were likely to have an increased risk of atherothrombotic events. (Platelet Function and genoType-Related Long-term progGosis in DES-treated Patients: A Consortium From Multi-centered Registries [PTRG-DES]; NCT04734028).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cardiology, Department of Internal Medicine, Heart Center, Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, South Korea; Division of Cardiology, Department of Intern…
- Division of Cardiology, Department of Internal Medicine, Chung-Ang University Gwangmyeong Hospital, Chung-Ang University College of Medicine, Gwangmyeong, South Korea.
- Division of Cardiology, Department of Internal Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
- Division of Cardiology, Department of Internal Medicine, Heart Center, Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, South Korea.
- Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, South Korea.
- Department of Cardiology, Cardiovascular Center, Korea University Anam Hospital, Korea University College of Medicine, Seoul, South Korea.
Zitieren
APA
Lee, S. H., Jeong, Y. H., Hong, D., Choi, K. H., Lee, J. M., Park, T. K., Yang, J. H., Hahn, J. Y., Choi, S. H., Gwon, H. C., Jeong, M. H., Kim, B. K., Joo, H. J., Chang, K., Park, Y., Ahn, S. G., Suh, J. W., Lee, S. Y., Cho, J. R., …, & PTRG-DES Registry Investigators (2023). Clinical Impact of CYP2C19 Genotype on Clopidogrel-Based Antiplatelet Therapy After Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 16(7), 829-843. https://doi.org/10.1016/j.jcin.2023.01.363
Vancouver
Lee SH, Jeong YH, Hong D, Choi KH, Lee JM, Park TK, et al. Clinical Impact of CYP2C19 Genotype on Clopidogrel-Based Antiplatelet Therapy After Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions. 2023;16(7):829-843. doi:10.1016/j.jcin.2023.01.363
BibTeX
@article{Lee2023,
author = {Lee, Seung Hun and Jeong, Young-Hoon and Hong, David and Choi, Ki Hong and Lee, Joo Myung and Park, Taek Kyu and Yang, Jeong Hoon and Hahn, Joo-Yong and Choi, Seung-Hyuck and Gwon, Hyeon-Cheol and Jeong, Myung Ho and Kim, Byeong-Keuk and Joo, Hyung Joon and Chang, Kiyuk and Park, Yongwhi and Ahn, Sung Gyun and Suh, Jung-Won and Lee, Sang Yeub and Cho, Jung Rae and Her, Ae-Young and Kim, Hyo-Soo and Kim, Moo Hyun and Lim, Do-Sun and Shin, Eun-Seok and Song, Young Bin and PTRG-DES Registry Investigators, PTRG-DES Registry Investigators},
title = {Clinical Impact of CYP2C19 Genotype on Clopidogrel-Based Antiplatelet Therapy After Percutaneous Coronary Intervention},
journal = {JACC: Cardiovascular Interventions},
year = {2023},
volume = {16},
number = {7},
pages = {829--843},
doi = {10.1016/j.jcin.2023.01.363}
}
EUVIMED